MedtechLedger currently links 104 FDA records to the applicant name Edwards Lifesciences, LLC. The collection includes 2 510(k) clearances. It includes 9 original PMA approvals. 26 entries are PMA supplements. 67 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Sep 26, 1991 to Oct 28, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Changes described in PMA records
The FDA record for P150048/S104 is a 30-day notice supplement, reason listed as process change affecting manufacturer, sterilizer, packager or supplier. The reported purpose is implementing an alternative supplier of a chemical manufacturing aid, linked to the INSPIRIS RESILIA aortic valve (11500A), KONECT RESILIA aortic valve conduit (AVC) (11060A) and MITRIS RESILIA mitral valve under product code LWR.
The identifier P150048 places this change within the existing PMA for the Edwards Lifesciences devices named, but the decision is a supplement, not a new approval of the whole system. The record does not identify the chemical aid, name either supplier, describe the manufacturing step, or give data on device safety or clinical performance. The purpose is reported by the applicant in the source statement and is not independent proof of safety or effectiveness.
The record carries decision code OK30 dated 2026-10-28, giving no further grounds for the decision.
FDA approval-order wording
implementing an alternative supplier of a chemical manufacturing aid
Oct 28, 2026 · 30-Day NoticeEdwards Lifesciences, LLC filed PMA supplement P200015/S084 for the SAPIEN 3 Transcatheter Heart Valve (9600TFX), a percutaneously delivered pulmonary valve prosthesis under product code NPV. The FDA record lists it as a 30-Day Notice with decision OK30, dated 2026-10-28. The supplement reason field cites a process change involving manufacturer, sterilizer, packager, or supplier, and the statement describes implementing an alternative supplier of a chemical manufacturing aid.
The supplement number ties this action to PMA P200015, but it is a notice about a supplier change, not an original approval of the valve system. The fields do not name the chemical manufacturing aid, the prior or replacement supplier, the affected manufacturing step, or any supporting data. The reported purpose does not by itself establish safety or clinical effectiveness, and no clinical or regulatory conclusion beyond this descriptive record is supported.
The available source does not specify which category—manufacturer, sterilizer, packager, or supplier—applies, nor identify the device component affected. Researchers should treat the stated purpose as the applicant's notice content rather than corroborated evidence of device performance.
FDA approval-order wording
implementing an alternative supplier of a chemical manufacturing aid
Oct 28, 2026 · 30-Day NoticeThis 30-Day Notice for supplement S210 to PMA P140031 records a process change: implementing an alternative supplier of a chemical manufacturing aid. The affected devices are the Edwards SAPIEN 3 Transcatheter Heart Valve (9600TFX) and the Edwards SAPIEN 3 Ultra Transcatheter Heart Valve (9750TFX), both percutaneously delivered aortic valve prostheses under product code NPT.
The notice does not state which chemical manufacturing aid, which manufacturing step, or which supplier is involved. The FDA decision field reads "OK30," but the source does not define that code. This supplement is not a new approval of the valve systems and does not establish safety or effectiveness; it only reports the supplier change.
FDA approval-order wording
implementing an alternative supplier of a chemical manufacturing aid
Oct 28, 2026 · 30-Day NoticeThe FDA record for P230013/S034 describes a 30-day notice, dated 2026-10-28, with a reported purpose of implementing an alternative supplier of a chemical manufacturing aid. The listed supplement reason is a process change covering manufacturer, sterilizer, packager or supplier. The applicant is Edwards Lifesciences, LLC, and the product code is NPW, in the cardiovascular specialty.
The identifier ties the notice to the original PMA P230013, and the title names the Edwards EVOQUE tricuspid valve replacement system (9850EV). That relationship identifies the affected filing but does not make this supplement a new approval of the whole system, and a manufacturing notice is not an original PMA. The record does not name the chemical manufacturing aid, the prior or replacement supplier, affected lots or models, or any supporting data. The stated purpose is not independent proof of safety or clinical effectiveness, and the record supports no clinical or regulatory conclusion beyond this description.
FDA approval-order wording
implementing an alternative supplier of a chemical manufacturing aid
Oct 28, 2026 · 30-Day NoticeThis 30-day notice for supplement S228 to PMA P860057 states that the change is implementing an alternative supplier of a chemical manufacturing aid. The affected device is the Carpentier-Edwards PERIMOUNT Theon RSR Pericardial Aortic Bioprosthesis with ThermaFix tissue process (2800TFX), a replacement heart valve under product code DYE.
The notice does not describe the chemical manufacturing aid, the previous or alternative supplier, or any resulting process validation. It also does not state that safety or clinical effectiveness was independently demonstrated. The supplement type is a process change involving manufacturer, sterilizer, packager, or supplier, and it does not constitute a new approval of the valve system.
FDA approval-order wording
implementing an alternative supplier of a chemical manufacturing aid
Oct 28, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.